The OJC Episode 23: ASCO GI Special

Pinterest LinkedIn Tumblr +

Special episode dedicated to ASCO GI Symposium

Today’s podcast is a Special Episode focused on the recent ASCO GI Symposium. We’ve analysis from a range of experts including  Jeanne Tie, Nick Pavlakis, Jeremy Shapiro, Matthew Burge, Christos Karapetis, Tim Price and of course our hosts, Eva Segelov, Craig Underhill and Hans Prenen. Hans presented at ASCO GI so he chats us through his paper in the Quick Bites section.

With the usual top quality banter and expert analysis from our Interviewees and Hosts, you are in for another great episode of The Oncology Journal Club!

Its over an hour so we’ve added timestamp chapters so you can easily navigate to each segment and speaker, and return to the podcast if you need to listen in chunks.  (Please use the ‘bullet point’ style button in the player above to access these. We hope this is helpful.).  

Thanks to everyone who participated and thanks to all our listeners, we hope you enjoy today’s entertaining and informative episode. And a big thank you to the indefatigable Craig Underhill for co-ordinating this epic episode.

About The Oncology Journal Club:

We have taken an old concept and updated it with a new format. In each episode a team of expert contributors will review topical journal papers and interview special guests who are leaders in their fields to help keep you informed of the latest developments on the go.

With The Oncology Podcast – and The Oncology Journal Club in particular – we are aiming to deliver oncology news differently,” Rachael Babin, Editor-in-Chief, Oncology News.

The Oncology Journal Club is hosted by Professor Eva Segelov, from Monash University. Eva is joined by Dr Craig Underhill from Albury-Wodonga and Professor Hans Prenen from Antwerp, Belgium. We hope you enjoy listening and find this a valuable and entertaining resource.


This Week’s Abstracts:

  1. Henriksen, TV., et al. Circulating tumor DNA analysis for assessment of recurrence risk, benefit of adjuvant therapy, and early relapse detection after treatment in colorectal cancer patients. J Clin Oncol 39, 2021 (suppl 3; abstr 11). 10.1200/JCO.2021.39.3_suppl.11. Access online here
  2. Katz, MHG., et al. Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas. J Clin Oncol 39, 2021 (suppl 3; abstr 377). 10.1200/JCO.2021.39.3_suppl.377. Access online here
  3. Yoshida, K., et al. Confirmed three-year RFS and OS of the randomized trial of adjuvant S-1 versus S-1 plus docetaxel after curative resection of pStage III gastric cancer (JACCRO GC-07). J Clin Oncol 39, 2021 (suppl 3; abstr 159). 10.1200/JCO.2021.39.3_suppl.159. Access online here.
  4. Wainberg, Z.A., et al. Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT). J Clin Oncol 39, 2021 (suppl 3; abstr 160). 10.1200/JCO.2021.39.3_suppl.160. Access online here.
  5. Shiu, K-K., et al. KEYNOTE-177: Phase III randomized study of pembrolizumab versus chemotherapy for microsatellite instability-high advanced colorectal cancer. J Clin Oncol 39, 2021 (suppl 3; abstr 6). 10.1200/JCO.2021.39.3_suppl.6. Access online here. 
  6. Rahma, O.E., et al. NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally-advanced rectal cancer (LARC)—Pembrolizumab experimental arm (EA) primary results. J Clin Oncol 39, 2021 (suppl 3; abstr 8). 10.1200/JCO.2021.39.3_suppl.8. Access online here. 
  7. Javle, M.M., et al. Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement. J Clin Oncol 39, 2021 (suppl 3; abstr 265). 10.1200/JCO.2021.39.3_suppl.265. Access online here. 
  8. Dogan, I., et al. Temozolomide and capecitabine (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors. J Clin Oncol 39, 2021 (suppl 3; abstr 366). 10.1200/JCO.2021.39.3_suppl.366. Access online here. 

This Week’s Quick Bites:

  1. Chung, H.C., et al. LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors: Results from the gastric cancer cohort. J Clin Oncol 39, 2021 (suppl 3; abstr 230). 10.1200/JCO.2021.39.3_suppl.230. Access online here. 
  2. Gomez-Roca, C., et al. LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort. J Clin Oncol 39, 2021 (suppl 3; abstr 94). 10.1200/JCO.2021.39.3_suppl.94. Access online here. 
  3. Villanueva, L., et al. Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase II LEAP-005 study. J Clin Oncol 39, 2021 (suppl 3; abstr 321). 10.1200/JCO.2021.39.3_suppl.321. Access online here
  4. Wang, F., et al. Camrelizumab in combination with apatinib as second-line treatment for advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study. J Clin Oncol 39, 2021 (suppl 3; abstr 215). 10.1200/JCO.2021.39.3_suppl.215. Access online here. 
  5. Wang, W., et al. Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma: A cost-effectiveness analysis. J Clin Oncol 39, 2021 (suppl 3; abstr 295). 10.1200/JCO.2021.39.3_suppl.295. Access online here. 
  6. Prenen, H., et al. Updated data from alloSHRINK phase I first-in-human study evaluating CYAD-101, an innovative non-gene edited allogeneic CAR-T in mCRC. J Clin Oncol 39, 2021 (suppl 3; abstr 74). 10.1200/JCO.2021.39.3_suppl.74. Access online here. 

This Week’s Team:

Professor Eva Segelov

Eva Segelov

Professor Eva Segelov is a Medical Oncologist and is Director of Oncology at Monash University and Monash Health, Melbourne, Victoria, previously Senior Medical Oncologist at St Vincent’s Hospital, St Vincent’s Private Hospital and St Vincent’s Clinic and Associate Professor of Medicine, University of New South Wales.

Eva has an interest in academic clinical trials in GI and breast cancer and has been a member of the AGITG since 2003. She has clinical trials expertise, links with national and international trials groups, and extensive experience with adult medical education.

 

Dr Craig Underhill

Craig Underhill

Dr Craig Underhill completed his Bachelor of Medicine and Surgery in 1987 at Melbourne University. He completed medical oncology training in Melbourne and worked as the Senior Clinical Research Registrar at Guy’s Hospital, London.

In 1998 arrived in Albury-Wodonga and established a medical oncology practice and clinical trials unit which has developed expertise and infrastructure to ensure the initiation of high quality trials. The research Unit lead by Dr Underhill has twice been awarded NSW Premier’s Award for Innovation in Cancer Clinical Trials, the inaugural award in 2009 and then again in 2012.

Dr Underhill chaired a working party that was instrumental in securing $65 million in federal funding for The Albury Wodonga Regional Cancer Centre which opened in September 2016.

Dr Underhill is the VCCC Regional Oncology Lead and advocates for the increased access to clinical trials for regional Victorians and leads the VCCC teletrials program.

Professor Hans Prenen

Hans Prenen

Professor Hans Prenen is a medical oncologist and head of the phase 1 – early clinical trials unit at the Antwerp University Hospital in Belgium. He is a member of several scientific organisations, published many scientific oncology papers in prestigious journals and is regularly invited for lectures at national and international meetings.  His interests are clinical trials and translational research with a focus on digestive oncology.

 

 

Associate Professor Jeanne Tie

Jeanne Tie

A/Prof Jeanne Tie is the lower gastrointestinal medical oncology and trials lead at the Peter MacCallum Cancer Centre and senior research fellow in the Personalised Oncology Division at the Walter and Eliza Hall Institute of Medical Research. Her translational research focusses on personalising treatment for patients with colorectal cancer with prognostic and predictive biomarkers, in particular the clinical applications of circulating tumour DNA (ctDNA). She leads several ctDNA-based randomized clinical trials in colorectal cancer which aim to assess the clinical utility of ctDNA in guiding adjuvant treatment decision.

 

Professor Nick Pavlakis

Nick Pavlakis

Professor Nick Pavlakis is Senior Staff Specialist in the Department of Medical Oncology at Royal North Shore Hospital and conjoint Professor in the Faculty of Medicine University of Sydney. He is current Board Chair of the new Thoracic Oncology Group of Australasia (TOGA), member of the Upper GI Working Party of the Australasian Gastrointestinal Trials Group (AGITG) and is centre lead of the RNSH NET service. He has extensive experience in clinical research leadership in national and international clinical trials in lung cancer, mesothelioma and GI cancers with several current and ongoing collaborative group trials in lung cancer, gastric cancer and NETs. As co-chair of the Bill Walsh Translational Research Laboratories he is involved in translational research in in lung cancer, pancreas and gastric cancers.  Putting evidence into practice he has with experience in systematic reviews and clinical practice guideline development.

Associate Professor Jeremy Shapiro

Jeremy Shapiro

Graduating from Monash University in 1989, Associate Professor Shapiro trained at the Alfred Hospital, Monash Medical Centre, and the Peter MacCallum Cancer Institute, before travelling to the United States in 1996 to complete a 3 year research fellowship in Gastro-Intestinal Cancer at the National Cancer Institute.

Since his return, Dr Shapiro has continued his clinical research interests in Gastrointestinal cancer, whilst working as a medical oncologist at the Cabrini, and Alfred Hospitals in Melbourne, and as an Associate Professor in the Monash University, Department of Medicine.

He is a lead researcher in the Australian Gastro-Intestinal Tumour Group, recently chaired 3 large International trials in refractory colorectal cancer, is the principal investigator on several other gastro-intestinal cancer trials and is the author of > 100 peer reviewed publications.

Associate Professor Matthew Burge

Matthew Burge

Associate Professor Matt Burge is a medical oncologist based at RBWH with a strong interest in gastrointestinal malignancies.

Dr Burge trained as a medical oncologist in Brisbane before undertaking a fellowship in the UK in gastrointestinal cancer. He returned to Brisbane in 2006 and is currently staff specialist at the Royal Brisbane and Women’s Hospital, the Prince Charles Hospital and Rockhampton Base Hospital. He is also a visiting oncologist at the Mater Hospital in Rockhampton.

Dr Burge has a broad range of experience in most solid tumour types but has a particular interest in gastrointestinal malignancies. He is involved in a number of clinical trials at the Royal Brisbane Hospital across a range of malignancies.

Professor Christos Karapetis

Christos Karapetis

Professor Chris Karapetis is Network Director for Cancer Services in the Southern Area Local Health Network of Adelaide, and Head of the Department of Medical Oncology at the Flinders Medical Centre. He is also the Director of Clinical Research in Medical Oncology at the Flinders Medical Centre and the Flinders Centre for Innovation in Cancer, Flinders University. He practices as a senior consultant medical oncologist at the same institution where he was instrumental in the establishment of a Clinical Research Unit. Professor Karapetis has been the principal investigator on over 160 clinical trials. His interest in clinical research developed following a research fellowship at Guy’s Hospital in London. He has established research interests in the areas of lung cancer, gastro-intestinal malignancy, molecular targeted therapies, predictive biomarkers, epidemiology and clinical research methodology. He is an active contributor to clinical research conducted through the Australasian Gastrointestinal Trial Group (AGITG).

Professor Tim Price

Tim Price

Professor Tim Price trained in Medical oncology at the RAH and completed a Gastrointestinal Fellowship at The Royal Marsden Hospital and Institute of Cancer Research, London. He is currently Head of Clinical Oncology Research and Head of Unit of the combined Haematology and Medical Oncology Service at The Queen Elizabeth Hospital, Woodville. He has also positions as Visiting Medical Oncologist at Calvary Hospital North Adelaide, Western Hospital Henley Beach and Lyell McEwin Health Service. He is a Clinical Professor within the Faculty of Medicine, at the University of Adelaide.

Professor Price is a member of the National Panel of Examiners for the Royal College of Physicians and is an active participant in student teaching, postgraduate education and clinical research. He is also a member of several international and national cancer Gastrointestinal advisory boards and is the current Chair of the Australasian Gastrointestinal Trials Group (AGITG). He is also Chair of the current Cancer Council NHMRC Colorectal Guidelines committee and a board member of the New Zealand Gastrointestinal Cancer Institute.

Rachael Babin

Rachael Babin

Rachael Babin is Editor-in-Chief of The Oncology Newsletter and Publisher of www.oncologynews.com.au. For regular oncology updates for healthcare professionals, please subscribe to The Oncology Newsletter.

With thanks to Eva Segelov, Craig Underhill, Hans Prenen, Jeanne Tie, Nick Pavlakis, Jeremy Shapiro, Christos Karapetis, Tim Price and Graham Knowles.

Share.

About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.